ArticleAntimicrobial agents and chemotherapy2025
A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of
Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Case Commentary: When susceptibility is not enough in recurrentAntimicrobial agents and chemotherapy · 2026Article
- In vitro interactions of sulbactam/durlobactam in combination with meropenem, ceftazidime/avibactam, piperacillin/tazobactam, cefiderocol and fosfomycin against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Sulbactam-Durlobactam for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026Review
- Combinations of colistin and bacteriocins prevent the selection of colistin resistance in Acinetobacter baumannii.Communications biology · 2026Article
- Clinical Relevance of Antimicrobial Susceptibility Testing Methods in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Comparative in vitro analysis of sulbactam-durlobactam against extensively drug resistant (XDR) and non-XDR carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates collected from a tertiary care facility in North India.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Successful Use of Sulbactam-Durlobactam in Treating Carbapenem-Resistant Acinetobacter baumannii Pneumonia and Sepsis After Liver Transplantation: A Case Report.The American journal of case reports · 2026Article
- Real-World Clinical Outcomes of Sulbactam-Durlobactam Against Carbapenem-ResistantInfection and drug resistance · 2026Article
- New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam.Antimicrobial agents and chemotherapy · 2025Review
- Turning the Tide Against Carbapenem-resistantOpen forum infectious diseases · 2025Article
- Potential role of avibactam in restoring susceptibility in Escherichia coli with two copies of blaScientific reports · 2025Article
- Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?Antimicrobial agents and chemotherapy · 2025Article
- Sulbactam for carbapenem-resistantJAC-antimicrobial resistance · 2025Review
- Successful Treatment of OXA-23Infection and drug resistance · 2025Article
- Sulbactam-durlobactam combination therapy for carbapenem-resistantFrontiers in pharmacology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the ATTACK Phase 3 trial examining the efficacy of sulbactam (SUL)/durlobactam (DUR) to treat primarily
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.